Can Ligand Pharmaceuticals cover its short-term obligations?

Its current ratio is 21.28 — current assets exceed current liabilities.

Where does Ligand Pharmaceuticals's balance sheet data come from?

Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ligand Pharmaceuticals LGND Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$115.09M+140%	$174.93M+142%	$139.38M+119%	$67.67M+273%	$47.99M-4.2%
Short-term investments	$664.33M+313%	$558.59M+204%	$525.15M+237%	$177.35M-15.1%	$160.91M-38.2%
Accounts receivable, net	$53.38M+38.7%	$59.6M+55.3%	$57.56M+67.7%	$41.29M+10.2%	$38.49M+35.4%
Inventories	$13.27M-9.2%	$9.13M-35.3%	$11.9M-28.9%	$15.49M-17.0%	$14.61M-31.5%
Total current assets	$865.42M+180%	$832.27M+151%	$753.92M+144%	$352.95M+13.0%	$309.32M-16.2%
Property and equipment, net	$3.44M-4.9%	$3.57M-76.4%	$3.47M-77.0%	$3.63M-75.7%	$3.62M-76.1%
Goodwill	$101.54M0.0%	$101.54M-3.5%	$101.54M-3.5%	$101.54M-3.5%	$101.54M-3.5%
Intangible assets, net	$217.34M-15.9%	$225.44M-15.5%	$233.54M-15.0%	$250.13M-11.7%	$258.39M-11.3%
Total assets	$1.53B+69.2%	$1.56B+65.7%	$1.48B+54.7%	$948.6M+9.5%	$905.44M-0.9%
Accounts payable	$5.26M-1.9%	$3.24M-38.1%	$3.68M-21.6%	$8.58M+379%	$5.37M+183%
Deferred revenue	$621K+515%	$621K0.0%	$621K-46.1%	$111K—	$101K—
Total current liabilities	$40.67M-30.7%	$37.45M+0.9%	$30.54M+23.3%	$64.73M+249%	$58.68M+229%
Total liabilities	$3.94M-96.4%	$3.22M-97.1%	$526.6M+363%	$120.08M+31.7%	$109.9M+2.4%
Common stock	60M0.0%	60M+299,900%	60M0.0%	60M0.0%	60M0.0%
Retained earnings	$594.74M+30.3%	$608.09M+21.9%	$578.22M+9.1%	$461.38M-14.1%	$456.53M-22.5%
Total stockholders' equity	$997.32M+25.4%	$1.02B+22.5%	$950.17M+13.0%	$827.31M+6.7%	$795.59M-1.4%
Total liabilities and stockholders' equity	$1.53B+69.2%	$1.56B+65.7%	$1.48B+54.7%	$948.6M+9.5%	$905.44M-0.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Ligand Pharmaceuticals cover its short-term obligations?: Its current ratio is 21.28 — current assets exceed current liabilities.
Where does Ligand Pharmaceuticals's balance sheet data come from?: Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.